Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLB1 | P16278 | 4/20 | 0.50 |
| ▸ | GBA1 | P04062 | 4/20 | 0.38 |
| ▸ | SPHK1 | Q9NYA1 | 2/20 | 0.37 |
| ▸ | GUSB | P08236 | 1/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.35 |
| ▸ | S1PR1 | P21453 | 3/20 | 0.35 |
| ▸ | S1PR3 | Q99500 | 3/20 | 0.35 |
| ▸ | GBA2 | Q9HCG7 | 2/20 | 0.35 |
| ▸ | S1PR2 | O95136 | 2/20 | 0.35 |
| ▸ | S1PR4 | O95977 | 2/20 | 0.35 |
| ▸ | S1PR5 | Q9H228 | 2/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4684888 | 0.91 | GLB1 (0.44) | GLB1GBA1SPHK1GUSBCYP1A2 | |
| SCHEMBL9820849 | 0.89 | GLB1 (0.42) | GLB1GBA1SPHK1GUSBS1PR1 | |
| SCHEMBL23473144 | 0.88 | GLB1 (0.55) | GLB1GBA1SPHK1GUSBCYP1A2 | |
| Ammonia Solution, Strong SCHEMBL9805948 | 0.86 | GLB1 (0.53) | GLB1GBA1CYP1A2 | |
| SCHEMBL18863635 | 0.78 | GLB1 (0.49) | GLB1GBA1SPHK1GUSBS1PR1 | |
| SCHEMBL7288455 | 0.77 | GLB1 (0.33) | GLB1GBA1CYP1A2GBA2 | |
| SCHEMBL7288448 | 0.77 | CYP1A2 (0.33) | GLB1CYP1A2 | |
| SCHEMBL1463931 | 0.77 | — | — | |
| SCHEMBL6401642 | 0.77 | GLB1 (0.39) | GLB1GBA1 | |
| SCHEMBL18191101 | 0.76 | GLB1 (0.71) | GLB1GBA1SPHK1GUSBS1PR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030008914-A1 | PHARMACEUTICAL FORMULATIONS USEFUL TO TREAT INFLAMMATORY AND IMMUNE DISORDERS | MILLENNIUM PHARMACEUTICALS, INC. | 2003-01-09 | — | — | US | claimed |
| EP-1123095-A1 | PHARMACEUTICAL FORMULATIONS USEFUL TO TREAT INFLAMMATORY AND IMMUNE DISORDERS | Millennium Pharmaceuticals, Inc. (US) | 2001-08-16 | — | — | EP | claimed |
| WO-2000023071-A1 | PHARMACEUTICAL FORMULATIONS USEFUL TO TREAT INFLAMMATORY AND IMMUNE DISORDERS | LEUKOSITE, INC. (US) | 2000-04-27 | — | — | WO | claimed |
| US-7241571-B2 | Using adjustments in leukotriene biosynthetic profile as tool to diagnosis and treat cardiovasular disorders | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2007-07-10 | — | — | US | disclosed |
| WO-2007019283-A2 | IDENTIFICATION OF 5-LIPOXYGENASE EFFECTS ON OBESITY AND INSULIN RESISTANCE | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2007-02-15 | — | — | WO | disclosed |
| US-7074388-B2 | Water stabilized medicinal aerosol formulation | KOS LIFE SCIENCE, INC. (US) | 2006-07-11 | — | — | US | disclosed |
| EP-1569617-A1 | WATER STABILIZED MEDICINAL AEROSOL FORMULATION RELATED APPLICATIONS | Kos Life Sciences, Inc. (US) | 2005-09-07 | — | — | EP | disclosed |
| EP-1448794-A4 | IDENTIFICATION OF 5-LIPOXYGENASE AS A MAJOR GENE CONTRIBUTING TO ATHEROSCLEROSIS | UNIV CALIFORNIA (US) | 2005-06-01 | — | — | EP | disclosed |
| US-20040209288-A1 | Using adjustments in leukotriene biosynthetic profile as tool to diagnosis and treat cardiovasular disorders | FLOW CAPITAL CORP. (CA) | 2004-10-21 | — | — | US | disclosed |
| EP-1448794-A2 | IDENTIFICATION OF 5-LIPOXYGENASE AS A MAJOR GENE CONTRIBUTING TO ATHEROSCLEROSIS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2004-08-25 | — | — | EP | disclosed |
| WO-2004022035-A1 | WATER STABILIZED MEDICINAL AEROSOL FORMULATION RELATED APPLICATIONS | KOS PHARMACEUTICALS, INC. (US) | 2004-03-18 | — | — | WO | disclosed |
| US-5856323-A | PAF RECEPTOR ANTAGONISTS, INHIBITING THE ENZYME 5-LIPOXYGENASE | CYTOMED, INC. (US) | 1999-01-05 | — | — | US | disclosed |
| US-5648486-A | LIPOXYGENASE INHIBITORS | CYTOMED, INC. (US) | 1997-07-15 | — | — | US | disclosed |
| US-5648486-A | LIPOXYGENASE INHIBITORS | CYTOMED, INC. (US) | 1997-07-15 | — | — | US | disclosed |
| US-5434151-A | Treatment of immune and inflammatory disorders, aryl substituted tetrahydrofurans, tetrahydrothiophenes, cyclopentanes, pyrrolidines | CYTOMED, INC. (US) | 1995-07-18 | — | — | US | disclosed |
| EP-0650485-A1 | 2,5-DIARYL TETRAHYDRO-THIOPHENES, -FURANS AND ANALOGS FOR THE TREATMENT OF INFLAMMATORY AND IMMUNE DISORDERS | CYTOMED, INC. (US) | 1995-05-03 | — | — | EP | disclosed |
| EP-0650485-A1 | 2,5-DIARYL TETRAHYDRO-THIOPHENES, -FURANS AND ANALOGS FOR THE TREATMENT OF INFLAMMATORY AND IMMUNE DISORDERS | CYTOMED, INC. (US) | 1995-05-03 | — | — | EP | disclosed |
| US-5358938-A | 2,5-Diaryl tetrahydrofurans, tetrahydrothiophenes, 1,3-cyclo-pentanes and pyrrolidines | CYTOMED, INC. (US) | 1994-10-25 | — | — | US | disclosed |
| WO-1994001430-A1 | 2,5-DIARYL TETRAHYDRO-THIOPHENES, -FURANS AND ANALOGS FOR THE TREATMENT OF INFLAMMATORY AND IMMUNE DISORDERS | CYTOMED, INC. (US) | 1994-01-20 | — | — | WO | disclosed |
| WO-1994001430-A1 | 2,5-DIARYL TETRAHYDRO-THIOPHENES, -FURANS AND ANALOGS FOR THE TREATMENT OF INFLAMMATORY AND IMMUNE DISORDERS | CYTOMED, INC. (US) | 1994-01-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030008914-A1 | PHARMACEUTICAL FORMULATIONS USEFUL TO TREAT INFLAMMATORY AND IMMUNE DISORDERS | ALOX5, ALOX5AP, ALOX15 | GLB1 3302/4885GBA1 2212/4885SPHK1 357/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.